Esperion to Participate in Two Upcoming Virtual Investor Conferences
May 06 2021 - 8:00AM
Esperion (NASDAQ: ESPR), today announced that members of Esperion
management will participate in two upcoming virtual conferences
during the month of May.
Event: |
Bank of
America 2021 Healthcare Conference |
Date: |
May 13, 2021 |
Format: |
Presentation & 1:1 Investor meetings |
Time: |
10:15 a.m. ET |
|
|
Event: |
Morgan Stanley Life After Covid Thematic Conference II |
Date: |
May 20, 2021 |
Format: |
Presentation & 1:1 Investor meetings |
Time: |
11:15 a.m. ET |
Live audio webcasts of these events can be accessed
on the investor relations section of the Esperion website at
www.esperion.com/investors-media/events-presentations/. Replays of
the webcasts will be archived on the Company's website for 90 days
following the events.
ESPERION Therapeutics
ESPERION is The Lipid Management Company. Our goal is lipid
management for everybody, that’s why we work hard to make our
medicines easy to get, easy to take and easy to have. We discover,
develop and commercialize innovative medicines and combinations to
lower cholesterol, especially for patients whose needs aren’t being
met by the status quo. Our entrepreneurial team of industry leaders
is inclusive, passionate and resourceful. We are singularly focused
on managing cholesterol so you can improve your health easily. For
more information, please visit www.esperion.com and follow us on
Twitter at www.twitter.com/EsperionInc.
ESPERION Therapeutics’ Commitment to Patients with
Hyperlipidemia
High levels of LDL-C can lead to a build-up of fat and
cholesterol in and on artery walls (known as atherosclerosis),
potentially leading to cardiovascular events, including heart
attack and stroke. In the U.S., 96 million people, or more than 37
percent of the adult population, have elevated LDL-C. There are
approximately 18 million people in the U.S. living with elevated
levels of LDL-C despite taking maximally tolerated lipid-modifying
therapy — including individuals considered statin averse — leaving
them at high risk for cardiovascular events1. In the United States,
more than 50 percent of atherosclerotic cardiovascular disease
(ASCVD) patients and heterozygous familial hypercholesterolemia
(HeFH) patients who are not able to reach their guideline
recommended LDL-C levels with statins alone need less than a 40
percent reduction to reach their LDL-C threshold goal2.
ESPERION's mission as the Lipid Management Company is to deliver
oral, once-daily medicines that complement existing oral drugs to
provide the additional LDL-C lowering that these patients need.
References(1) ESPERION market research on file:
research project interviewing 350 physicians. ESPERION
Therapeutics, Inc. Sept-Oct 2018.(2) Data on file: analysis of
NHANES database. ESPERION Therapeutics, Inc. 2018.
Investor Contact:Kaitlyn
BroscoEsperioncorporateteam@esperion.com
Esperion Therapeutics (NASDAQ:ESPR)
Historical Stock Chart
From Jun 2024 to Jul 2024
Esperion Therapeutics (NASDAQ:ESPR)
Historical Stock Chart
From Jul 2023 to Jul 2024